H. pylori / peptic ulcer

h-pylori · society: ACG

← back to Gastroenterology & Hepatology

Summary

ACG 2024 guideline on H. pylori treatment in North America, replacing the 2017 version in response to rising clarithromycin/levofloxacin resistance and FDA approval of vonoprazan-based regimens. Bismuth quadruple therapy (BQT) for 14 days is preferred first-line when susceptibility is unknown; rifabutin triple therapy or vonoprazan-amoxicillin dual therapy are alternatives. Clarithromycin- and levofloxacin-containing regimens should be reserved for cases with documented susceptibility. Universal post-treatment test of cure is required.

Current guideline: ACG 2024 Treatment of H. pylori Infection · download Anki sub-deck

Versions

Table of contents